Chembio Diagnostics (CEMI) Receives Daily News Impact Rating of 0.24

Media stories about Chembio Diagnostics (NASDAQ:CEMI) have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Chembio Diagnostics earned a news sentiment score of 0.24 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.9373352149109 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the media stories that may have effected Accern Sentiment’s scoring:

Separately, ValuEngine raised Chembio Diagnostics from a “strong sell” rating to a “sell” rating in a research report on Friday, August 11th.

Shares of Chembio Diagnostics (CEMI) remained flat at $$6.75 during mid-day trading on Tuesday. The company’s stock had a trading volume of 11,700 shares, compared to its average volume of 20,668. The company has a current ratio of 3.54, a quick ratio of 2.19 and a debt-to-equity ratio of 0.01. Chembio Diagnostics has a twelve month low of $5.05 and a twelve month high of $7.05.

WARNING: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at

Chembio Diagnostics Company Profile

Chembio Diagnostics, Inc (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc, develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies.

Insider Buying and Selling by Quarter for Chembio Diagnostics (NASDAQ:CEMI)

Receive News & Ratings for Chembio Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics Inc. and related companies with's FREE daily email newsletter.

Leave a Reply